Daishin Balance No.6 Special Purpose Acquisition Co. Ltd

KQ:307750 Korea Drug Manufacturers - General
Market Cap
$159.52 Million
₩233.57 Billion KRW
Market Cap Rank
#19953 Global
#836 in Korea
Share Price
₩4655.00
Change (1 day)
-3.62%
52-Week Range
₩2850.00 - ₩4830.00
All Time High
₩22045.88
About

KUKJEON PHARMACEUTICAL Co., Ltd operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services. The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support. It develops electronic mate… Read more

Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) - Net Assets

Latest net assets as of September 2025: ₩98.41 Billion KRW

Based on the latest financial reports, Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) has net assets worth ₩98.41 Billion KRW as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩177.78 Billion) and total liabilities (₩79.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩98.41 Billion
% of Total Assets 55.35%
Annual Growth Rate 31.86%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 66.14

Daishin Balance No.6 Special Purpose Acquisition Co. Ltd - Net Assets Trend (2020–2024)

This chart illustrates how Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (2020–2024)

The table below shows the annual net assets of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd from 2020 to 2024.

Year Net Assets Change
2024-12-31 ₩97.42 Billion -0.04%
2023-12-31 ₩97.46 Billion +5.56%
2022-12-31 ₩92.32 Billion +11.03%
2021-12-31 ₩83.15 Billion +157.99%
2020-12-31 ₩32.23 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 157.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩30.37 Billion 31.18%
Common Stock ₩4.91 Billion 5.04%
Other Components ₩62.14 Billion 63.78%
Total Equity ₩97.42 Billion 100.00%

Daishin Balance No.6 Special Purpose Acquisition Co. Ltd Competitors by Market Cap

The table below lists competitors of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 96,421,535,430 to 97,419,913,560, a change of 998,378,130 (1.0%).
  • Net income of 1,736,210,520 contributed positively to equity growth.
  • Dividend payments of 490,691,520 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩1.74 Billion +1.78%
Dividends Paid ₩490.69 Million -0.5%
Other Changes ₩-247.14 Million -0.25%
Total Change ₩- 1.04%

Book Value vs Market Value Analysis

This analysis compares Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.34x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 5.99x to 2.34x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2020-12-31 ₩776.59 ₩4655.00 x
2021-12-31 ₩1694.56 ₩4655.00 x
2022-12-31 ₩1866.70 ₩4655.00 x
2023-12-31 ₩1965.01 ₩4655.00 x
2024-12-31 ₩1985.36 ₩4655.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Daishin Balance No.6 Special Purpose Acquisition Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 1.78%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 1.27%
  • • Asset Turnover: 0.64x
  • • Equity Multiplier: 2.18x
  • Recent ROE (1.78%) is below the historical average (2.22%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2020 -10.29% -4.11% 1.39x 1.79x ₩-6.54 Billion
2021 4.86% 4.73% 0.80x 1.29x ₩-4.28 Billion
2022 9.77% 8.63% 0.53x 2.14x ₩-211.90 Million
2023 5.00% 3.95% 0.54x 2.33x ₩-4.82 Billion
2024 1.78% 1.27% 0.64x 2.18x ₩-8.01 Billion

Industry Comparison

This section compares Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

  • Industry: Drug Manufacturers - General
  • Average net assets among peers: $138,724,008,377
  • Average return on equity (ROE) among peers: 3.90%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) ₩98.41 Billion -10.29% 0.81x $65.86 Million
PharmGen Science Inc (004720) $249.43 Billion 1.12% 0.46x $34.69 Million
Korean Drug Co. Ltd (014570) $65.05 Billion 5.99% 0.17x $14.60 Million
BCWORLD PHARM. Co. Ltd (200780) $101.69 Billion 4.58% 0.90x $19.54 Million